Here in Quantum we’ve developed an effective approach to hit identification with the help of our proprietary virtual screening technology. As described in the presentation below (yes, it’s clickable) we use the software to develop our own drug candidates, some of them are in the late pre-clinical stages. We believe that the potential of our software exceeds anything we could think of doing on our own and that is why we are happy to offer our services to anyone willing to find novel small molecules against any protein target with known 3d structure in as little as one month.

Quantum may help to find the protein target, analyze its structure, conformational stability, suggest possible binding sites for small molecules modulation of its function. We maintain our own diverse sets of drug-like molecules available from the major chemical compounds providers, or can use the known ZINC and NCBI datasets for the docking run to identify the hits. We can perform the preparations and the computational screening of millions compounds in about a month time harnessing essentially infinite resources provided by Amazon EC2 infrastructure.

Quantum has hit-identification, lead optimization and pre-clinical development expertise. We have established and often on-going relations with the best CROs. If required, we can help to order the compounds and set up the in-vitro studies. Once the hits are found and the activity is confirmed we can help all the way to meet your drug discovery goals.

We do not use single-size-fits-all model, tell us your story and we’ll find a way to collaborate, even if it is a graduate project! Do not waste on setting up a docking run on your own, fill the form below and we’ll do it right.

Quantum internet privacy statement are summarized here

References from our co-workers:

“Quantum team has worked well with my group to identify small molecule inhibitors that have therapeutic potential. His turnaround times have been excellent and his interactions have been positive”, Joseph Testa, Director, Human Genetics Program, Fox Chase Cancer Center

“We have worked with the team at Quantum to identify lead compounds which have antiviral activity against a panel of influenza and herpes viruses. Our screening has identified several small molecule compounds in the Quantum collection with marked anti-influenza activities in vitro”, Marylou Gibson, Owner, Virapur, LLC www.virapur.com

“I am involved in an early stage drug-development project togеther with Quantum. Its activity in the project is of highest scientific quality and at the same time very professional from business point of view. I would like to recommend Quantum as reliable and valuable collaborator in drug-development projects”, Maxim Skulachev, CEO, Mitotech LLC

“Quantum has helped tremendously in my anti-HIV effort. They managed to aid in the design of small molecule inhibitors to a very difficult HIV protein target, demonstrating that they have the foresight and scientific knowledge to tackle even the most challenging project. I would definitely (and actually do hope to) work Quantum again”, Simon Cocklin, Res. Assistant Professor, Drexel University College of Medicine

Recent Publications from our collaborations:

Molecular Biology, Drug Design:

1. Fedichev, Peter; Timakhov, Roman; Pyrkov, Tim; Getmantsev, Evgeny; Vinnik, Andrey. Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo [Internet]. Version 206. PLoS Currents: Influenza. 2011 Jul 11 [revised 2011 Aug 7]. Available from: http://knol.google.com/k/peter-fedichev/structure-based-drug-design-of-a-new/1nsjcj02vqpk8/1
2. Catherine Joce, Joshua A. Stahl, Mitesh Shridhar, Mark R. Hutchinson, Linda R. Watkins, Peter O. Fedichev and Hang Yin, Bioorganic & Medicinal Chemistry Letters, Volume 20, Issue 18, 15 September 2010, Pages 5411-5413